H 4 picoopa─Robust Chelate for 225 Ac/ 111 In Theranostics.

The nuclear decay characteristics of 225 Ac ( E α = 5-8 MeV, linear energy transfer (LET) = ∼100 keV/μm, t 1/2 = 9.92 days) are well recognized as advantageous for the treatment of primary and metastatic tumors; however, suitable chelation systems are required, which can accommodate this radiometal. Since 225 Ac does not possess any suitable low-energy, high abundance γ-ray emissions for nuclear imaging, there is a clear need for the development of other companion radionuclides with similar coordination characteristics and comparable half-lives, which can be applied in diagnostics. H 4 picoopa was designed and executed as a high-denticity ligand for chelation of [ 225 Ac]Ac 3+ , and the complexation characteristics have been explored through nuclear magnetic resonance (NMR) spectroscopy, solution thermodynamic stability studies, and radiolabeling. The ligand shows highly favorable complexation with La 3+ (pM = 17.6), Lu 3+ (pM = 21.3), and In 3+ (pM = 31.2) and demonstrates effective radiolabeling of both [ 225 Ac]Ac 3+ and [ 111 In]In 3+ ions achieving quantitative radiochemical conversions (RCCs) under mild conditions (RT, 10 min), accompanied by high serum stability (>97% radiochemical purity (RCP) over 6 days). A bifunctional analogue of H 4 picoopa was synthesized and conjugated to the Pip-Nle-CycMSH hex peptide for targeting of MC1R positive melanoma tumors. In vivo single-photon emission computed tomography (SPECT) and biodistribution studies of the 111 In-radiolabeled bioconjugate in mice bearing B16-F10 tumors showed good radiotracer stability, although improved tumor targeting could not be achieved for imaging purposes. This work highlights H 4 picoopa as a very promising platform for application of [ 225 Ac]Ac 3+ and [ 111 In]In 3+ as a theranostic pair and allows great versatility for the incorporation of other directing vectors. The logical synthetic approach reported here for bifunctional H 4 picoopa, involving an azide-functionalized covalent linker and Cu I -catalyzed alkyne-azide cycloaddition, allows for ease of optimization of bioconjugate pharmacokinetics and will be valuable for further radiopharmaceutical applications moving forward.